RxDoctor Payments Data

Ting-Lin Yang, MD

Dermatology · Bellingham, WANPI 1154771954

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $86,863 of the $124,294 with a category attached, or 69.9%. 24 manufacturers reported payments, led by AbbVie at 52.1% of the total. 2025 is the largest year on record at $78,618, more than ten times the $349 reported in 2019. Among dermatology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$124,294in general payments, 2019–2025

Across 478 payments — averaging $260.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65K
  • Lilly USA, LLC$41K
  • Regeneron Healthcare Solutions, Inc.$4K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Sanofi$3K
  • Arcutis Biotherapeutics, Inc.$2K
  • plus $5K from 18 others

What the payments were for

  • Consulting fees$11,6339%
  • Speaking & faculty fees$86,86370%
  • Travel & lodging$12,45910%
  • Food & beverage$12,56210%
  • Education$7791%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$124,294 in reported general payments places this provider in the 95th percentile of 323 dermatology providers in Washington.

See all dermatology providers in Washington

Medicare billing

Part B allowed, 2024
$514,489
Medicare patients
847
Services billed
6,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab61$233,279
RinvoqUpadacitinib18$124,898
Fluorouracil101$6,425
Clobetasol Propionate114$5,336
Tacrolimus33$4,152
Doxycycline Hyclate61$3,669
Ketoconazole118$2,120
Metronidazole44$2,081
Tretinoin20$1,807
Calcipotriene12$1,394
Minoxidil141$1,117
Triamcinolone Acetonide134$1,069
ValacyclovirValacyclovir Hcl36$786
Hydroxychloroquine Sulfate25$622
Fluconazole41$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$64,776$124,89818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 dermatology providers in Washington.

Other dermatology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →